Streetbeat News

Products Services

CANF

Can-Fite Biopharma announced that its Phase 3 study for Namodenoson, a treatment for advanced liver cancer, is now recruiting at 31 medical centers. Namodenoson has received Orphan Drug status from both the FDA and the European Medicines Agency, as well as FDA Fast Track status. Additionally, a compassionate use program is ongoing in Israel and Romania.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 11:18 am

ACN

Accenture has entered a three-year partnership with Major League Cricket champions MI New York, becoming its principal partner. The partnership will feature the Accenture logo on MI New York's match and training jerseys and will leverage Accenture's digital services and consulting expertise to enhance team performance through innovative solutions and data-driven strategies.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 11:15 am

ESTA

The FDA's Center for Devices and Radiological Health has completed its review of Establishment Labs' premarket approval application for Motiva Implants. The application is deemed approvable pending an acceptable FDA inspection of the manufacturing facilities, which has been rescheduled to occur within the next thirty days.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 11:13 am

ALT

Altimmune, Inc. (NASDAQ:ALT) presented new data on pemvidutide's benefits for liver disease and obesity at the EASL Congress. The data showed significant improvements in liver health and body composition, suggesting pemvidutide's potential as a differentiated treatment for MASH and obesity.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 11:12 am

HROW

Harrow (NASDAQ:HROW) announced positive results from its ESSENCE-2 open-label extension clinical study for VEVYE, a cyclosporine ophthalmic solution for treating dry eye disease. The study demonstrated significant improvements in efficacy endpoints and high patient satisfaction, with minimal adverse events.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 11:10 am

AVBP

ArriBent BioPharma has entered into a collaboration with Jiangsu Alphamab Biopharmaceuticals, a subsidiary of Alphamab Oncology, to develop cancer-focused antibody-drug conjugates. The deal includes upfront and potential milestone payments to Alphamab of up to $615.5 million.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 11:09 am

SYTA

Siyata Mobile has announced a partnership with JD Telecom to expand the distribution of its SD7 handsets, VK7 vehicle kits, and related components.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 11:09 am

ACET

Adicet Bio shares are trading higher after the company was granted FDA Fast Track Designation to ADI-001 in lupus nephritis.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 11:07 am

DTIL

Precision BioSciences, Inc. (NASDAQ:DTIL) will present preclinical data on its PBGENE-HBV clinical candidate at the EASL Congress, showcasing the effectiveness and safety of its ARCUS® platform for treating chronic hepatitis B.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 11:07 am

ACET

Adicet Bio announced that the FDA has granted Fast Track Designation to ADI-001 for the treatment of relapsed/refractory Class III or Class IV Lupus Nephritis. This designation aims to expedite the development and review of drugs for serious conditions with unmet medical needs.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 11:04 am